지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2022.6
- 수록면
- 539 - 544 (6page)
- DOI
- 10.3349/ymj.2022.63.6.539
이용수
초록· 키워드
오류제보하기
Purpose: To date, no study has compared the effects of adding sodium glucose cotransporter-2 (SGLT-2) inhibitors to the combinationof metformin plus dipeptidyl peptidase-4 (DPP-4) inhibitors to the effects of adding other conventional anti-diabetic drugs(ADDs) to the dual therapy. We aimed to compare the effect of adding SGLT-2 inhibitors with that of adding sulfonylurea (SU) intype 2 diabetes (T2D) patients inadequately controlled with metformin plus DPP-4 inhibitors.
Materials and Methods: This study was designed to evaluate the non-inferiority of SGLT-2 inhibitor to SU as an add-on therapyto the dual combination of metformin plus DPP-4 inhibitors. A total of 292 T2D patients who started SU or SGLT-2 inhibitors as anadd-on therapy to metformin plus DPP-4 inhibitors due to uncontrolled hyperglycemia, defined as glycated hemoglobin (HbA1c)≥7%, were recruited. After propensity score matching, 90 pairs of patients remained, and 12-week changes in HbA1c levels were reviewedto assess glycemic effectiveness. Data from these patients were analyzed retrospectively.
Results: After 12 weeks of triple therapy, both groups showed significant changes in HbA1c levels, with a mean of -0.9% in eachgroup. The inter-group difference was 0.01% [95% confidence interval (CI): -0.26–0.27], and the upper limit of the 95% CI was withinthe limit for non-inferiority (0.40%). There were no inter-group differences in the changes of liver enzyme levels and kidney function.
Conclusion: Adding SGLT-2 inhibitors is not inferior to adding SU as a third-line ADD to metformin plus DPP-4 inhibitor combinationtherapy.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
제2형 당뇨병 환자에서 Metformin과 병용한 Sodium-Glucose Cotransporter 2 Inhibitors와 Dipeptidyl Peptidase 4 Inhibitors의 효능 비교
병원약사회지
2020 .01
-
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
Diabetes and Metabolism Journal
2019 .01
-
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Endocrinology and Metabolism
2021 .01
-
Effect of Sodium-Glucose Cotransporter-2 Inhibitors versus Dipeptidyl Peptidase 4 Inhibitors on Cardiovascular Function in Patients with Type 2 Diabetes Mellitus and Coronary Artery Disease
Journal of Obesity & Metabolic Syndrome
2019 .01
-
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Endocrinology and Metabolism
2021 .01
-
제2형 당뇨병 환자에서 장기간의 Sodium-glucose Cotransporter 2 억제제 치료가 신장기능에 미치는 효과
대한내과학회지
2020 .08
-
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2021 .01
-
Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
Korean Circulation Journal
2020 .01
-
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2024 .09
-
Financial Benefits of Renal Dose-Adjusted Dipeptidyl Peptidase-4 Inhibitors for Patients with Type 2 Diabetes and Chronic Kidney Disease
Endocrinology and Metabolism
2024 .08
-
Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: a Meta-Analysis
지질·동맥경화학회지
2021 .01
-
SGLT2 억제제와 케톤산증: 발생기전과 대처
대한내과학회지
2017 .01
-
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement
Kidney Research and Clinical Practice
2020 .01
-
Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors
Diabetes and Metabolism Journal
2022 .01
-
Beneficial effects of posttransplant dipeptidyl peptidase-4 inhibitor administration after pancreas transplantation to improve β cell function
Annals of Surgical Treatment and Research
2021 .09
-
SGLT2 억제제와 만성 콩팥병
대한내과학회지
2024 .04
-
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis
Journal of Obesity & Metabolic Syndrome
2021 .12
-
Metformin에 추가로 병용되는 SGLT2 inhibitors의 효능과 안전성에 관한 고찰
한국임상약학회지
2018 .01
-
Use of dapagliflozin in patients with advanced diabetic kidney disease
Kidney Research and Clinical Practice
2018 .01
-
Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin
Diabetes and Metabolism Journal
2015 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0